Verastem, Inc.

VSTM

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001526119

None

No letter

6 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $246.4M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, thin data; fortress balance sh...
Inputs computable	6 of 13
Graded from	filings received through Mar 4, 2026 259 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$7.42 2026-11-17; market equity $935.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 4, 2026

We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States ("U.S."), the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer ("LGSOC") who have received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK received accelerated approval in the U.S. on May 8, 2025.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 8.9						
Gross profitability	not computable	32.8%				
latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(41.4%)	(6.7%)		8.9	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 1						
Solvency, sleeve percentile 74.5						
Altman Z double-prime	(15.71)	0.31		71.6	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	(149.50x)	(3.61x)		95.9	74	2025-12-31
Current ratio	3.09x	2.68x		56.2	781	2025-12-31
Growth and financing, sleeve percentile 45.8						
Revenue growth, three-year compound	not computable	9.6%				
four consecutive annual observations are required						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 10						
Reinvestment rate	not computable	33.9%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	37.4%	3.2%		11.5	663	2025-12-31
Net share issuance, one year	70.6%	1.6%		80.1	625	2026-02-27

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 70.6%
Thin data	6 of 13 grade factors are computable; minimum is 7
Fortress balance sheet	cash minus debt is 48,094,000 USD; Altman Z is not used

What the price implies

at the 2026-11-17 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(14.8%)	(1.7%)	40
Distance from 52-week high	(30.4%)	(30.5%)	50
EBIT to enterprise value	(21.2%)	0.5%	21
Free cash flow yield	(11.2%)	0.5%	26
Book value to price	0.01	0.28	12
Sales to price	0.03	0.36	6
Composite equity issuance, five years	217.6%	13.5%	92
Relative strength against the sector, log excess return	(0.33)	(0.19)	40
Twelve-month failure probability, CHS model	0.21%	0.06%	75

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	pass

Cash, filings, liquidity

Cash and equivalents	$172.8M
Operating cash flow, four quarters	-$159.6M
Months of runway	13.0
Days since last periodic filing	13 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$21.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$26.7M	2018-12-31	2021-03-18	10-K	21-003211
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$165,000	2018-12-31	2019-03-12	10-K	19-001852
3	assets	us-gaap:Assets	$277.2M	2018-12-31	2020-03-11	10-K	20-002421
4	operating income	us-gaap:OperatingIncomeLoss	-$115.0M	2024-12-31	2026-03-04	10-K	26-023444
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$130.5M	2024-12-31	2026-03-04	10-K	26-023444
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$185,000	2024-12-31	2026-03-04	10-K	26-023444
7	total debt	us-gaap:LongTermDebt	$40.7M	2024-12-31	2026-03-04	10-K	26-023444
8	book equity	us-gaap:StockholdersEquity	-$28.9M	2024-12-31	2026-03-04	10-K	26-023444
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$88.8M	2024-12-31	2026-03-04	10-K	26-023444
10	total debt	us-gaap:LongTermDebt	$40.1M	2023-12-31	2025-03-20	10-K	25-003372
11	book equity	us-gaap:StockholdersEquity	$57.4M	2023-12-31	2026-03-04	10-K	26-023444
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$77.9M	2023-12-31	2025-03-20	10-K	25-003372
13	net income	us-gaap:NetIncomeLoss	-$209.5M	2025-12-31	2026-03-04	10-K	26-023444
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$137.5M	2025-12-31	2026-03-04	10-K	26-023444
15	assets	us-gaap:Assets	$246.4M	2025-12-31	2026-03-04	10-K	26-023444
16	assets	us-gaap:Assets	$101.5M	2024-12-31	2026-03-04	10-K	26-023444
17	current assets	us-gaap:AssetsCurrent	$223.4M	2025-12-31	2026-03-04	10-K	26-023444
18	current liabilities	us-gaap:LiabilitiesCurrent	$72.3M	2025-12-31	2026-03-04	10-K	26-023444
19	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.2B	2025-12-31	2026-03-04	10-K	26-023444
20	operating income	us-gaap:OperatingIncomeLoss	-$170.1M	2025-12-31	2026-03-04	10-K	26-023444
21	book equity	us-gaap:StockholdersEquity	$57.2M	2025-12-31	2026-03-04	10-K	26-023444
22	liabilities	us-gaap:Liabilities	$189.2M	2025-12-31	2026-03-04	10-K	26-023444
23	depreciation amortization	us-gaap:Depreciation	$26,000	2024-12-31	2026-03-04	10-K	26-023444
24	interest expense	us-gaap:InterestExpense	$1.1M	2025-12-31	2026-03-04	10-K	26-023444
25	revenue	us-gaap:Revenues	$30.9M	2025-12-31	2026-03-04	10-K	26-023444
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.0M	2024-12-31	2025-03-20	10-K	25-003372
27	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.6M	2022-12-31	2025-03-20	10-K	25-003372
28	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.1M	2021-12-31	2023-03-14	10-K	23-003738
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$28,000	2024-12-31	2026-03-04	10-K	26-023444
30	current assets	us-gaap:AssetsCurrent	$95.0M	2024-12-31	2026-03-04	10-K	26-023444
31	current liabilities	us-gaap:LiabilitiesCurrent	$31.0M	2024-12-31	2026-03-04	10-K	26-023444
32	current assets	us-gaap:AssetsCurrent	$143.7M	2023-12-31	2025-03-20	10-K	25-003372
33	current liabilities	us-gaap:LiabilitiesCurrent	$26.4M	2023-12-31	2025-03-20	10-K	25-003372
34	assets	us-gaap:Assets	$149.7M	2023-12-31	2025-03-20	10-K	25-003372
35	assets	us-gaap:Assets	$95.0M	2022-12-31	2024-03-14	10-K	24-003250
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	87,835,106	2026-02-27	2026-03-04	10-K	26-023444
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	51,486,705	2025-03-19	2025-03-20	10-K	25-003372

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.